Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Deal Size: $33.6 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 16, 2020
The financing will allow Ona Therapeutics to complete the pre-clinical development in a variety of tumor types and to move its lead candidate into first clinical studies in patients with metastatic cancer in 2023.